Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.

ABSTRACT:

SUBMITTER: Tiacci E 

PROVIDER: S-EPMC8550943 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature